Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7918636 | 0.92 | MAPT (0.54) | MAPTALDH1A1SMN1; SMN2KDM4ETDP1 | |
| SCHEMBL26207326 | 0.89 | MAPT (0.54) | MAPTALDH1A1SMN1; SMN2KDM4ETDP1 | |
| SCHEMBL15569388 | 0.89 | MAPT (0.62) | MAPTALDH1A1SMN1; SMN2KDM4E | |
| Hydrochloric Acid SCHEMBL28671520 | 0.85 | SMN1; SMN2 (0.55) | MAPTALDH1A1SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL4172495 | 0.85 | MAPT (0.58) | MAPTALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL25697926 | 0.85 | MAPT (0.58) | MAPTALDH1A1SMN1; SMN2KDM4ECYP3A4 | |
| Ethyl Isonipecotate SCHEMBL30020730 | 0.85 | MAPT (0.48) | MAPTALDH1A1SMN1; SMN2KDM4ETDP1 | |
| SCHEMBL378609 | 0.84 | MAPT (0.57) | MAPTALDH1A1SMN1; SMN2KDM4ETDP1 | |
| SCHEMBL15956633 | 0.84 | MAPT (0.57) | MAPTALDH1A1SMN1; SMN2KDM4E | |
| Hydrochloric Acid SCHEMBL5071255 | 0.84 | MAPT (0.57) | MAPTALDH1A1SMN1; SMN2KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119977980-A | Novel modulators of 5-hydroxytryptamine receptor 7 and methods of use thereof | 英联邦高等教育系统坦普尔大学 | 2025-05-13 | — | — | CN | disclosed |
| CN-110177776-B | Novel modulators of 5-hydroxytryptamine receptor 7 and methods of use thereof | 英联邦高等教育系统坦普尔大学 | 2025-02-28 | — | — | CN | disclosed |
| US-11731987-B2 | Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof | INSILICO MEDICINE IP LIMITED (HK) | 2023-08-22 | — | — | US | disclosed |
| US-20230192688-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (HK) | 2023-06-22 | — | — | US | disclosed |
| EP-3630756-B1 | PROCESS FOR THE PREPARATION OF AN UMECLIDINIUM SYNTHESIS INTERMEDIATE | OLON SPA (IT) | 2021-12-29 | — | — | EP | disclosed |
| WO-2021130732-A1 | ANTIBACTERIAL QUINOLINES | TECNIMEDE - Sociedade Técnico-medicinal, SA (PT) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021112461-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE AGENT | 주식회사 엘지화학 | 2021-06-10 | — | — | WO | disclosed |
| EP-3150578-B1 | NOVEL PYRROLIDINE COMPOUND AND APPLICATION AS MELANOCORTIN RECEPTOR AGONIST | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-10-14 | — | — | EP | disclosed |
| EP-3660010-A1 | S1P MODULATING AGENTS | Biogen MA Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| EP-3150590-B1 | S1P MODULATING AGENTS | BIOGEN MA INC (US) | 2019-10-16 | — | — | EP | disclosed |
| US-20040097570-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | NEUROSEARCH A/S | 2004-05-20 | — | — | US | disclosed |
| EP-0874809-B1 | CARBAMOYLOXY DERIVATIVES OF MUTILINE AND THEIR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2003-08-27 | — | — | EP | disclosed |
| EP-0934316-B1 | AZABICYCLIC CARBAMOYLOXY MUTILIN DERIVATIVES FOR ANTIBACTERIAL USE | SMITHKLINE BEECHAM PLC (GB) | 2002-10-16 | — | — | EP | disclosed |
| US-6239175-B1 | Carbamoyloxy derivatives of mutiline and their use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-29 | — | — | US | disclosed |
| US-6121281-A | Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-09-19 | — | — | US | disclosed |
| US-6020368-A | MICROBIOCIDES | HINKS JEREMY DAVID (US) | 2000-02-01 | — | — | US | disclosed |
| EP-0934316-A1 | AZABICYCLIC CARBAMOYLOXY MUTILIN DERIVATIVES FOR ANTIBACTERIAL USE | SMITHKLINE BEECHAM PLC (GB) | 1999-08-11 | — | — | EP | disclosed |
| EP-0874809-A1 | CARBAMOYLOXY DERIVATIVES OF MUTILINE AND THEIR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 1998-11-04 | — | — | EP | disclosed |
| WO-1998005659-A1 | AZABICYCLIC CARBAMOYLOXY MUTILIN DERIVATIVES FOR ANTIBACTERIAL USE | SMITHKLINE BEECHAM PLC (GB) | 1998-02-12 | — | — | WO | disclosed |
| WO-1997025309-A1 | CARBAMOYLOXY DERIVATIVES OF MUTILINE AND THEIR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 1997-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192688-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | EGLN3, EGLN2, EGLN1 | MAPT 2807/4885ALDH1A1 1538/4885SMN1; SMN2 4522/4885 |
| US-20040097570-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | GABRA1, GABRA2, GABRA4 | MAPT 906/4885ALDH1A1 977/4885SMN1; SMN2 759/4885 |
| US-11731987-B2 | Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof | EGLN3, EGLN2, EGLN1 | MAPT 2807/4885ALDH1A1 1538/4885SMN1; SMN2 4522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.